Nature Communications

Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial

2026-05-13

Full text

DOI https://doi.org/10.1038/s41467-026-72125-0